Suppliers and packagers for VOQUEZNA

VOQUEZNA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151	NDA	Phathom Pharmaceuticals Inc.	81520-100-30	30 TABLET in 1 BOTTLE, PLASTIC (81520-100-30)	2023-11-10
Phathom	VOQUEZNA	vonoprazan fumarate	TABLET;ORAL	215151	NDA	Phathom Pharmaceuticals Inc.	81520-200-30	30 TABLET in 1 BOTTLE, PLASTIC (81520-200-30)	2023-11-10

Voquezna Drug Manufacturing and Supply Chain Analysis

Last updated: February 19, 2026

This report details the supply chain and manufacturing landscape for Voquezna (vonoprazan), a potassium-competitive acid blocker. Key suppliers, manufacturing processes, and regulatory considerations are identified.

Who Manufactures Voquezna?

Takeda Pharmaceutical Company is the primary manufacturer and marketer of Voquezna. The drug is produced at Takeda's facilities and through contract manufacturing organizations (CMOs).

Primary Manufacturer

• Takeda Pharmaceutical Company: Holds the marketing authorization and oversees global production and distribution of Voquezna.

Contract Manufacturing Organizations (CMOs)

Takeda utilizes CMOs for various stages of drug substance and drug product manufacturing. Specific CMOs engaged for Voquezna production are proprietary, but common practice within the pharmaceutical industry involves outsourcing to specialized facilities for:

• Active Pharmaceutical Ingredient (API) Synthesis: Production of vonoprazan fumarate.
• Formulation and Drug Product Manufacturing: Creation of the final dosage form (tablets).
• Packaging and Labeling: Preparing the finished product for distribution.

Companies operating in the pharmaceutical contract manufacturing space with capabilities relevant to small molecule oral solid dosage forms are potential partners. These include:

• Catalent
• Thermo Fisher Scientific (Patheon)
• Lonza
• Boehringer Ingelheim BioXcellence
• AbbVie (for specific services)

The selection of CMOs is contingent on adherence to Good Manufacturing Practices (GMP), regulatory compliance (FDA, EMA), quality control, and capacity.

What are the Key Starting Materials and Intermediates for Vonoprazan Synthesis?

The synthesis of vonoprazan fumarate involves several key starting materials and intermediates. While proprietary synthesis routes exist, a generalized understanding of the chemical building blocks is essential. The synthesis typically involves heterocyclic chemistry.

Chemical Structure of Vonoprazan

Vonoprazan is chemically designated as 1-(5-(2-fluorophenyl)-1-((pyridin-3-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine. The fumarate salt is the commonly used form.

Representative Synthesis Pathway Components

A typical synthesis might involve:

1. Pyridine-3-sulfonyl chloride: A key reagent for introducing the pyridinylsulfonyl group.
2. Pyrrole derivatives: Specific substituted pyrrole rings form the core of the molecule. These often require multi-step synthesis themselves, starting from simpler organic compounds.
3. 2-Fluorobenzaldehyde or related compounds: Used to introduce the 2-fluorophenyl moiety.
4. Methylamine: For the N-methylmethanamine side chain.
5. Fumaric acid: To form the fumarate salt.

Suppliers for these types of chemical building blocks are typically fine chemical manufacturers specializing in organic synthesis. Examples include:

• Sigma-Aldrich (Merck KGaA): A broad supplier of research chemicals and fine chemicals.
• Thermo Fisher Scientific: Offers a wide range of chemical reagents and intermediates.
• Specialty Chemical Manufacturers: Companies focused on custom synthesis and production of specific organic intermediates. Examples include:
  • Wuxi AppTec
  • Pharmacosmos
  • Lonza (custom synthesis division)

The fumarate salt is typically formed in the final stages of API production.

What Regulatory Considerations Govern Voquezna Manufacturing?

Voquezna manufacturing is subject to stringent regulations by global health authorities to ensure product safety, efficacy, and quality.

Key Regulatory Bodies and Standards

• U.S. Food and Drug Administration (FDA): Oversees manufacturing in the United States. Requires adherence to Current Good Manufacturing Practices (cGMP) outlined in 21 CFR Parts 210 and 211.
• European Medicines Agency (EMA): Regulates manufacturing within the European Union. Requires compliance with EudraLex Volume 4, which details EU GMP guidelines.
• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: Regulates manufacturing for the Japanese market.
• Ministry of Health, Labour and Welfare (MHLW) - Japan: Another key regulatory body in Japan.
• Other National Regulatory Authorities: Relevant in countries where Voquezna is marketed.

Critical Aspects of Regulatory Compliance

• Facility Inspections: Regular inspections of manufacturing sites (Takeda-owned and CMOs) by regulatory agencies.
• Drug Master Files (DMFs): Manufacturers of API and key intermediates maintain DMFs submitted to regulatory agencies, detailing manufacturing processes, quality control, and stability data.
• Quality Management Systems (QMS): Robust QMS are required, encompassing change control, deviation management, CAPA (Corrective and Preventive Actions), and validation.
• Supply Chain Security: Measures to prevent counterfeiting and ensure the integrity of raw materials and finished products throughout the supply chain.
• Environmental, Health, and Safety (EHS) Regulations: Compliance with local and international EHS standards in manufacturing operations.

Takeda is responsible for ensuring all its suppliers and CMOs meet these regulatory requirements.

What is the Role of Excipients in Voquezna Formulations?

Excipients are inactive ingredients that play a crucial role in the formulation of Voquezna tablets, impacting stability, bioavailability, and manufacturability.

Typical Excipients in Oral Solid Dosage Forms

Common excipients used in tablet formulations, which are likely to be present in Voquezna, include:

• Binders: Hold the ingredients together (e.g., hydroxypropyl cellulose, povidone).
• Fillers/Diluents: Add bulk to the tablet (e.g., microcrystalline cellulose, lactose).
• Disintegrants: Help the tablet break apart in the gastrointestinal tract (e.g., croscarmellose sodium, sodium starch glycolate).
• Lubricants: Prevent sticking to tablet press machinery (e.g., magnesium stearate, stearic acid).
• Glidants: Improve powder flow (e.g., colloidal silicon dioxide).
• Coating Agents: For tablet coating (e.g., hypromellose, polyethylene glycol, titanium dioxide).

Key Suppliers of Pharmaceutical Excipients

Major global suppliers of pharmaceutical-grade excipients include:

• Ashland: Offers a range of binders, disintegrants, and coating systems.
• BASF: A leading supplier of excipients, including binders, fillers, and solvents.
• Colorcon: Specializes in film coating systems and excipients for solid dosage forms.
• Croda International: Provides specialty excipients.
• DuPont: Offers various functional excipients.
• Roquette: A producer of starch-based and cellulose-based excipients.

The specific excipients used in Voquezna are detailed in the drug's approved labeling and regulatory filings. Takeda's procurement strategy would involve qualifying and selecting multiple suppliers for critical excipients to ensure supply continuity and quality.

What are the Distribution and Logistics Channels for Voquezna?

The distribution of Voquezna involves a complex network to ensure timely and secure delivery to pharmacies, hospitals, and ultimately, patients.

Distribution Model

• Wholesalers and Distributors: Takeda primarily works with major pharmaceutical wholesalers to distribute Voquezna to retail pharmacies and healthcare institutions. In the U.S., these include:
  • McKesson
  • Cardinal Health
  • AmerisourceBergen
• Direct Distribution: In certain markets or for specific channels (e.g., hospital systems), Takeda may engage in direct distribution.
• Specialty Pharmacies: For specific indications or patient populations, distribution may be channeled through specialty pharmacies.

Logistics and Cold Chain Requirements

Voquezna is an oral solid dosage form and does not typically require stringent cold chain storage (<2°C to 8°C). Standard pharmaceutical warehousing and transportation conditions are applicable, focusing on:

• Temperature and Humidity Control: Maintaining ambient controlled conditions (e.g., 20°C to 25°C).
• Security: Measures to prevent diversion and counterfeiting.
• Traceability: Track-and-trace systems (e.g., serialization) to monitor product movement from manufacturer to dispenser.

Logistics providers specializing in pharmaceutical transportation are critical partners. These may include:

• DHL Supply Chain
• UPS Healthcare
• Kuehne+Nagel

Takeda's supply chain management team is responsible for overseeing these logistics operations, ensuring compliance with Good Distribution Practices (GDP).

Key Takeaways

• Takeda Pharmaceutical Company is the primary manufacturer of Voquezna, leveraging both internal manufacturing capabilities and contract manufacturing organizations (CMOs) for API synthesis, formulation, and packaging.
• The synthesis of vonoprazan fumarate relies on specific organic chemical starting materials and intermediates, sourced from fine chemical manufacturers.
• Manufacturing processes are strictly regulated by global health authorities (FDA, EMA, PMDA) requiring adherence to cGMP standards and robust quality management systems.
• Excipients are essential for Voquezna's formulation, with a range of suppliers providing binders, fillers, disintegrants, lubricants, and coating agents.
• Voquezna is distributed primarily through pharmaceutical wholesalers, with standard temperature and humidity-controlled logistics, and robust traceability measures.

Frequently Asked Questions

1. How does Takeda ensure the quality and reliability of its contract manufacturers for Voquezna?

Takeda implements a rigorous supplier qualification program that includes audits of manufacturing facilities, review of quality systems, and ongoing performance monitoring to ensure CMOs meet cGMP and regulatory standards.

2. What is the typical lead time for sourcing key starting materials for vonoprazan synthesis?

Lead times for key starting materials can vary significantly, ranging from a few weeks to several months, depending on the complexity of the chemical synthesis, supplier capacity, and current market availability.

3. Are there any specific U.S. FDA or EMA regulations that are particularly critical for Voquezna API manufacturing?

Critical regulations include ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), 21 CFR Part 210/211 for the U.S., and EudraLex Volume 4 for the EU, which detail stringent requirements for API production, quality control, and documentation.

4. How are potential supply chain disruptions for Voquezna mitigated?

Takeda diversifies its supplier base for critical raw materials and excipients, maintains safety stock inventories, and develops contingency plans with CMOs to address unforeseen events such as natural disasters, geopolitical issues, or raw material shortages.

5. What is the role of serialization and track-and-trace technologies in the Voquezna supply chain?

Serialization and track-and-trace technologies are crucial for ensuring product authenticity, preventing counterfeiting, and enabling efficient recalls. They provide unique identifiers for each saleable unit, allowing for real-time tracking of the drug's journey from manufacturing to the point of dispensing.

---

Cited Sources

[1] Takeda Pharmaceutical Company. (n.d.). Global Network. Retrieved from [Takeda's official website or investor relations section for manufacturing/supply chain information - specific URL would be required if available]. [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Drugs. Retrieved from [FDA's official website]. [3] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Volume 4. Good manufacturing practice. Retrieved from [EMA's official website]. [4] ICH Harmonisation. (n.d.). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH official website or relevant regulatory agency website].